Release Date: 07/07/16 13:19 Summary: Letter to Shareholders-KBL.AX Price Sensitive: No Download Document 1.14MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%